Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

MLA

Gambacorti-Passerini, Carlo, et al. “Bosutinib Efficacy and Safety in Chronic Phase Chronic Myeloid Leukemia after Imatinib Resistance or Intolerance: Minimum 24-Month Follow-Up.” American Journal of Hematology, vol. 89, no. 7, July 2014, pp. 732–42. EBSCOhost, https://doi.org/10.1002/ajh.23728.

APA

Gambacorti-Passerini, C., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Masszi, T., Assouline, S., Durrant, S., Kantarjian, H. M., Khoury, H. J., Zaritskey, A., Shen, Z.-X., Jin, J., Vellenga, E., Pasquini, R., Mathews, V., Cervantes, F., Besson, N., Turnbull, K., Leip, E., & Kelly, V. (2014). Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. American Journal of Hematology, 89(7), 732–742. https://doi.org/10.1002/ajh.23728

Chicago

Gambacorti-Passerini, Carlo, Tim H. Brümmendorf, Dong-Wook Kim, Anna G. Turkina, Tamas Masszi, Sarit Assouline, Simon Durrant, et al. 2014. “Bosutinib Efficacy and Safety in Chronic Phase Chronic Myeloid Leukemia after Imatinib Resistance or Intolerance: Minimum 24-Month Follow-Up.” American Journal of Hematology 89 (7): 732–42. doi:10.1002/ajh.23728.